A. Falanga, L. Russo, V. Milesi, and A. Vignoli, Mechanisms and risk factors of thrombosis in cancer, Critical Reviews in Oncology, vol.118, pp.79-83, 2017.

P. A. Kyrle, Predicting recurrent venous thromboembolism in cancer: is it possible?, Thrombosis Research. 1 mai, vol.133, pp.17-22, 2014.

M. Carrier, A. Lazo-langner, S. Shivakumar, V. Tagalakis, P. L. Gross et al., Clinical challenges in patients with cancer-associated thrombosis: Canadian expert consensus recommendations, Curr Oncol. févr, vol.22, issue.1, pp.49-59, 2015.

H. Al-samkari and J. M. Connors, The Role of Direct Oral Anticoagulants in Treatment of CancerAssociated Thrombosis, Cancers. août, vol.10, issue.8, p.271, 2018.

D. Farge, H. Bounameaux, B. Brenner, F. Cajfinger, P. Debourdeau et al., International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. The Lancet Oncology, vol.17, pp.452-66, 2016.

G. H. Lyman, A. A. Khorana, N. M. Kuderer, A. Y. Lee, J. I. Arcelus et al., Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update, Journal of Clinical Oncology. 10 juin, vol.31, issue.17, pp.2189-204, 2013.

. Inca, Thrombose et Cancer -Recommandation

F. Posch, O. Königsbrügge, C. Zielinski, I. Pabinger, and C. Ay, Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants, Thrombosis Research. 1 sept, vol.136, issue.3, pp.582-591, 2015.

D. Sur,

A. Nationale-de-médecine, Dictionnaire médical de l'Académie de Médecine

L. Fondation-contre and . Cancer, Qu'est-ce que le cancer?

. Inca, Les stades du cancer

D. Sur,

. Inca, Les grades du cancer

D. Sur,

Y. Dargaud, Thrombose hémostase et cancer : les mécanismes physiopathologiques en jeu, Oncologie. déc, vol.14, issue.12, pp.638-681, 2012.

I. Thrombose-veineuse,

D. Sur,

, Fédération Française de Cardiologie. Embolie pulmonaire, 2016.

D. Sur,

S. Eichinger, Cancer associated thrombosis: risk factors and outcomes, Thrombosis Research. avr, vol.140, pp.12-19, 2016.

P. De-moerloose, G. Reber, and J. Pugin, Activation et inhibition de la coagulation : que se passe-t-il en cas de coagulopathie intravasculaire disséminée ? Réanimation, vol.11, pp.584-90, 2002.

P. Sié, Physiologie et sémiologie de l'hémostase

D. Sur,

A. El-mestari, Physiologie de l'hémostase

D. Sur,

K. Date, J. Hall, J. Greenman, A. Maraveyas, and L. A. Madden, Tumour and microparticle tissue factor expression and cancer thrombosis, Thrombosis Research. févr, vol.131, issue.2, pp.109-124, 2013.

G. T. Gerotziafas, La maladie thromboembolique veineuse chez les patients atteints d'une hémopathie maligne État des lieux sur l'ampleur du problème, Hématologie. 1 janv, vol.25, issue.1, pp.16-28, 2019.

A. Delobel, Traitement des maladies thromboemboliques veineuses dans le cancer : étude observationnelle sur 220 patients, 2016.

M. Sevestre-pietri, Maladie Thrombo-Embolique Veineuse et Cancer. La lettre du médecin vasculaire, pp.28-39, 2016.

J. Cedervall, A. Hamidi, A. Olsson, and . Platelets, NETs and cancer, Thrombosis Research. avr, vol.164, pp.148-52, 2018.

A. Falanga, M. Marchetti, and L. Russo, The mechanisms of cancer-associated thrombosis, Thrombosis Research. févr, vol.135, pp.8-11, 2015.

B. Jude, S. Susen, C. Zavadski, and N. Trillot, Les thrombophilies constitutionnelles

. Biomnis, Mutation g.20210 du gène de la prothrombine

D. Sur,

J. Emmerich,

, Bull Acad Natl Med, vol.187, issue.1, pp.32-33, 2003.

C. E. Chee, A. A. Ashrani, R. S. Marks, T. M. Petterson, K. R. Bailey et al., Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study, Blood. 19 juin, vol.123, issue.25, pp.3972-3980, 2014.

S. Seng, Z. Liu, S. K. Chiu, T. Proverbs-singh, G. Sonpavde et al., Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and metaanalysis, J Clin Oncol. 10 déc, vol.30, issue.35, pp.4416-4442, 2012.

M. Japkowicz, T. San, and J. Gligorov, Cancers, thromboses veineuses et traitements antiangiogéniques, VEGF actu, issue.19, p.3, 2010.

. Netgen, Scores cliniques pour le risque de récidive de maladie veineuse thromboembolique (MVTE) et pour les relations cancer-MVTE*. Revue Médicale Suisse, vol.12, pp.363-370, 2016.

H. A. Liebman, Cancer prognosis in patients with venous thromboembolism (VTE) and patients with clinical and laboratory biomarkers predictive of VTE risk, Thromb Res, vol.164, issue.1, pp.19-22, 2018.

. Ansm, Les anticoagulants en France en 2014: état des lieux, synthèse et surveillance, 2014.

G. Bouvenot, J. Bounhoure, J. Montastruc, and A. Vacheron, Rapport sur les anticoagulants oraux directs (AOD) (antérieurement appelés « nouveaux anticoagulants oraux » ou NACO), juin, vol.198, issue.6, pp.1157-95, 2014.

V. Hoptimal and . Pradaxa,

F. Mear, Les nouveaux anticoagulants oraux : modalités de prescription et perception par les généralistes, 2014.

. Thériaque, Monographie PRADAXA 75mg

D. Sur,

. Thériaque, Monographie ELIQUIS 5mg

D. Sur,

. Thériaque, Monographie XARELTO 10mg

D. Sur,

L. Pierard and M. Sprynger, Place des nouveaux anticoagulants oraux directs, Revue Médicale Suisse, vol.10, pp.1562-1569, 2014.

N. J. Short and J. M. Connors, New Oral Anticoagulants and the Cancer Patient, The Oncologist. 1 janv, vol.19, issue.1, pp.82-93, 2014.

J. L. Fitzgerald and L. G. Howes, Drug Interactions of Direct-Acting Oral Anticoagulants, Drug Safety. sept, vol.39, issue.9, pp.841-846, 2016.

L. Bertoletti, E. Ollier, C. Duvillard, X. Delavenne, M. Beyens et al., Direct oral anticoagulants: Current indications and unmet needs in the treatment of venous thromboembolism, Pharmacol Res, vol.118, pp.33-42, 2017.

S. Mantha, E. Laube, Y. Miao, D. M. Sarasohn, R. Parameswaran et al., Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study, J Thromb Thrombolysis. févr, vol.43, issue.2, pp.166-71, 2017.

H. Riess, P. Prandoni, S. Harder, S. Kreher, and R. Bauersachs, Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: Potential for drug-drug interactions, Crit Rev Oncol Hematol. déc, vol.132, pp.169-79, 2018.

H. Autorité-de-santé, Résumé des Caractéristiques du Produit Rivaroxaban 15mg

C. S. Miller, S. M. Grandi, A. Shimony, K. B. Filion, and M. J. Eisenberg, Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation, Am J Cardiol. 1 août, vol.110, issue.3, pp.453-60, 2012.

M. C. Vedovati, F. Germini, G. Agnelli, and C. Becattini, Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis, Chest. févr, vol.147, issue.2, pp.475-83, 2015.

N. Kraaijpoel and M. Carrier, How I treat cancer-associated venous thromboembolism, Blood. 24 janv, vol.133, issue.4, pp.291-299, 2019.

A. Bellesoeur, A. Thomas-schoemann, M. Allard, D. Smadja, M. Vidal et al., Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: Clinical consequences, Crit Rev Oncol Hematol. sept, vol.129, pp.102-114, 2018.

S. A. Mousa, Comparative Pharmacodynamic Assessment of the Antiangiogenesis Activity of Heparin and Low-Molecular-Weight Heparin Fractions: Structure-Function Relationship, Clinical and Applied Thrombosis/Hemostasis. janv, vol.19, issue.1, pp.48-54, 2013.

S. Mousa and L. Petersen, Anti-cancer properties of low-molecular-weight heparin: Preclinical evidence, Thrombosis and Haemostasis, vol.102, issue.08, pp.258-67, 2009.

J. A. Ross, M. M. Miller, R. Hernandez, and C. M. , Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancerrelated venous thromboembolism: A retrospective analysis, Thrombosis Research. 1 févr, vol.150, pp.86-95, 2017.

G. Agnelli, H. R. Buller, A. Cohen, A. S. Gallus, T. C. Lee et al., Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial, J Thromb Haemost. déc, vol.13, issue.12, pp.2187-91, 2015.

A. A. Khorana, S. Noble, A. Lee, G. Soff, G. Meyer et al., Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH, Journal of Thrombosis and Haemostasis, vol.16, issue.9, pp.1891-1895, 2018.

C. Ay, J. Beyer-westendorf, and I. Pabinger, Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants, Annals of Oncology. 1 juin, vol.30, issue.6, pp.897-907, 2019.

F. Grandoni and L. Alberio, Direct Oral Anticoagulant Drugs: On the Treatment of Cancer-Related Venous Thromboembolism and their Potential Anti-Neoplastic Effect, Cancers (Basel). 5 janv, vol.11, issue.1, 2019.

A. M. Young, A. Marshall, J. Thirlwall, O. Chapman, A. Lokare et al., Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D), J Clin Oncol. 10 juill, vol.36, issue.20, pp.2017-2040, 2018.

E. Ramacciotti, L. B. Agati, R. A. Caffaro, G. G. Volpiani, R. D. Lopes et al., Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019?, Clin Appl Thromb Hemost. déc, vol.25, pp.1-7, 2019.

H. Autorité-de-santé, Commission de la Transparence ELIQUIS 2.5 -5mg

G. Agnelli, H. R. Buller, A. Cohen, M. Curto, A. S. Gallus et al., Oral apixaban for the treatment of acute venous thromboembolism, N Engl J Med. 29 août, vol.369, issue.9, pp.799-808, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00932477

T. Nassif, J. Banchs, S. W. Yusuf, and E. Mouhayar, Acute haemorrhagic tamponade in cancer patients receiving direct oral anticoagulant: case series, Eur Heart J Case Rep. 20 déc, vol.1, issue.2, 2017.

B. Pegourie, L. Karlin, L. Benboubker, F. Orsini-piocelle, M. Tiab et al., Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study, American Journal of Hematology, vol.94, issue.6, pp.635-675, 2019.